# Liom Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/liom-health

- Industry: Medical Devices & Equipment
- Headquarters: Pfaffikon, Switzerland
- Website: www.liom.com/
- Total disclosed funding: $16M
- Latest round: Series A (Dec 21, 2025)
- Investors on record: 1

## About

Based in Pfäffikon, Switzerland, and founded in 2017 by CEO Leo Grünstein, Spiden AG, d.b.a. Liom operates as a healthcare technology company that develops a technology platform to analyze biomarkers and drugs in real time through spectroscopic measurements of body fluids, especially blood. In December 2024, Liom raised USD 25 million in series A funding from unspecified investors.

Liom provides a non-invasive glucose monitoring device integrated with various health metrics. This wearable technology provides continuous glucose measurements without the need for skin penetration, allowing for real-time tracking of glucose levels. The device also monitors other health aspects such as metabolic responses, activity levels, cardiovascular health, and sleep quality. It delivers predictive alerts and insights into meal optimization, fitness tracking, and mental well-being. In December 2025, Liom Health AG raised CHF 13 million in series A funding from Red Bull Ventures.

The company plans to utilize the December 2025 funding to support miniaturization of proprietary Raman spectroscopy platform and transition to product development and commercialization.

## Funding rounds

- Series A, Dec 21, 2025, $16M — Red Bull Ventures

## Investors

- Red Bull Ventures (https://capitalatlas.ai/funds/red-bull-ventures) — Series A